Real‐world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load

Abstract

TDF for highly viraemic mothers was well tolerated and reduced vertical transmission of HBV in a real-world setting. There were no safety concerns during the postpartum 28-week follow-up. Registry number: Chinese Clinical Trial Registration No. ChiCTR-OIC-17010869.